Secondary objectives
acute infection symptoms, weight gain, malaria
MALARIA, SECONDARY, INTESTINAL INFLAMMATION, MALNUTRITION
In addition to the primary aim, the trial has secondary aims in assessing other health effects of AZI on the treated population. The secondary aims are as follows:To evaluate the effect of receiving two-dose and four-dose AZI MDA on AMR.To evaluate the impact of AZI MDA to 1–11-month-old infants on their period prevalence of acute infection symptoms.To evaluate the impact of AZI MDA to 1–11-month-old infant on their linear growth, weight gain, and prevalence of malnutrition.To investigate mechanisms of AZI action by testing hypotheses onwhether or not AZI MDA eliminates malaria parasitaemia.whether or not AZI MDA increases mean blood hemoglobin concentration.whether or not AZI MDA reduces systemic or intestinal inflammation in asymptomatic children.Also, an integrated LAKANA feasibility study aims to provide comprehensive policy advice to decision makers on possible strategies to implement an AZI intervention as a national program should the trial yield positive clinical results. Feasibility study is not described in this SAP due to many aspects of the study being conditional on the trial results.